Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
38
EQ Quote, Financials, Valuation and Earnings
Last price:
$0.65
Seasonality move
:
35.05%
Day range:
$0.60 - $0.65
52-week range:
$0.56 - $3.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.50x
P/B ratio:
0.99x
Volume:
108.7K
Avg. volume:
130.2K
1-year change:
-1.7%
Market cap:
$22.9M
Revenue:
$36.1M
EPS (TTM):
-$0.14
Analysts' Opinion
-
Consensus RatingEquillium has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Equillium has an estimated upside of 416.16% from its current price of $0.65.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.65.
Fair Value
-
According to the consensus of 3 analysts, Equillium has 416.16% upside to fair value with a price target of -- per share.
EQ vs. S&P 500
-
Over the past 5 trading days, Equillium has underperformed the S&P 500 by -4.95% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Equillium does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Equillium has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Equillium reported revenues of $12.2M.
Earnings Growth
-
Equillium has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Equillium reported earnings per share of -$0.00.
Enterprise value:
-3M
EV / Invested capital:
-0.13x
Price / LTM sales:
0.50x
EV / EBIT:
--
EV / Revenue:
-0.07x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-10.18%
Net Income Margin (TTM):
-10.05%
Return On Equity:
-20.35%
Return On Invested Capital:
-20.35%
Operating Margin:
-5.58%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $42.6M | $45.9M | $8.9M | $12.2M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$51.5M | -$9.3M | -$6.8M | -$3.6M | -$679K | |
| EBITDA | -$74.7M | -$6.8M | -$4.5M | -$3.2M | $28K | |
| Diluted EPS | -$2.34 | -$0.24 | -$0.14 | -$0.11 | -$0.00 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $92.2M | $92.2M | $46.8M | $53.9M | $33.6M | |
| Total Assets | $92.4M | $92.5M | $48.6M | $55.2M | $34.5M | |
| Current Liabilities | $5.1M | $7.8M | $14.9M | $28.2M | $11.1M | |
| Total Liabilities | $14.3M | $16.7M | $20.5M | $31.1M | $11.3M | |
| Total Equity | $78.1M | $75.8M | $28.2M | $24.1M | $23.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$46.6M | $11.6M | -$21.4M | -$1.9M | -$7.7M | |
| Cash From Investing | -$5.2M | $7.8M | $2.3M | $11M | $12M | |
| Cash From Financing | $366K | -$10.7M | $170K | -$260K | -- | |
| Free Cash Flow | -$46.9M | $11.6M | -$21.5M | -$1.9M | -$7.7M | |
EQ
Sector
Market Cap
$22.9M
$46.1M
Price % of 52-Week High
19.87%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-1.71%
-30.52%
Beta (5-Year)
1.782
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$0.63
200-day SMA
Sell
Level
$1.14
Bollinger Bands (100)
Sell
Level
0.67 - 1.01
Chaikin Money Flow
Buy
Level
61M
20-day SMA
Sell
Level
$0.69
Relative Strength Index (RSI14)
Sell
Level
42.12
ADX Line
Sell
Level
13.26
Williams %R
Neutral
Level
-54.963
50-day SMA
Sell
Level
$0.82
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
174.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.1688)
Sell
CA Score
(Annual)
Level (-1.4578)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.8703)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Stock Forecast FAQ
In the current month, EQ has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EQ average analyst price target in the past 3 months is --.
-
Where Will Equillium Stock Be In 1 Year?
According to analysts, the consensus estimate is that Equillium share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Equillium?
Analysts are divided on their view about Equillium share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Equillium is a Sell and believe this share price will drop from its current level to --.
-
What Is Equillium's Price Target?
The price target for Equillium over the next 1-year time period is forecast to be -- according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EQ A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Equillium is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of EQ?
You can purchase shares of Equillium via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Equillium shares.
-
What Is The Equillium Share Price Today?
Equillium was last trading at $0.65 per share. This represents the most recent stock quote for Equillium. Yesterday, Equillium closed at $0.65 per share.
-
How To Buy Equillium Stock Online?
In order to purchase Equillium stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
